{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:29:43Z","timestamp":1740122983519,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10928-021-09758-9","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T03:42:20Z","timestamp":1620790940000},"page":"615-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concentration-QTc analysis with two or more correlated baselines"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-947X","authenticated-orcid":false,"given":"Yasushi","family":"Orihashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"9758_CR1","unstructured":"ICH E14 Implementation Working Group (2015) The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions & Answers (R3). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Q_As_R3__Step4.pdf"},{"key":"9758_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q et al (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45:383\u2013397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9758_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/pst.2083","volume":"20","author":"Y Orihashi","year":"2021","unstructured":"Orihashi Y, Kumagai Y, Shiosakai K (2021) Novel concentration-QTc models for early clinical studies with parallel placebo controls: a simulation study. Pharm Stat 20:375\u2013389. https:\/\/doi.org\/10.1002\/pst.2083","journal-title":"Pharm Stat"},{"key":"9758_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/biostatistics\/kxp046","volume":"11","author":"MG Kenward","year":"2010","unstructured":"Kenward MG, Roger JH (2010) The use of baseline covariates in crossover studies. Biostatistics 11:1\u201317. https:\/\/doi.org\/10.1093\/biostatistics\/kxp046","journal-title":"Biostatistics"},{"key":"9758_CR5","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1002\/sim.5614","volume":"32","author":"K Lu","year":"2013","unstructured":"Lu K (2013) An efficient and robust analysis of covariance model for baseline adjustment in parallel-group thorough QT\/QTc studies. Stat Med 32:2406\u20132418. https:\/\/doi.org\/10.1002\/sim.5614","journal-title":"Stat Med"},{"key":"9758_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/pst.1647","volume":"13","author":"K Lu","year":"2014","unstructured":"Lu K (2014) An efficient analysis of covariancemodel for crossover thorough QT studies with period-specific pre-dose baselines. Pharm Stat 13:388\u2013396. https:\/\/doi.org\/10.1002\/pst.1647","journal-title":"Pharm Stat"},{"key":"9758_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0962280214520728","volume":"24","author":"S Senn","year":"2015","unstructured":"Senn S (2015) Various varying variances: the challenge of nuisance parameters to the practising biostatistician. Stat Methods Med Res 24:403\u2013419. https:\/\/doi.org\/10.1177\/0962280214520728","journal-title":"Stat Methods Med Res"},{"key":"9758_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0091270007307881","volume":"48","author":"CE Garnett","year":"2008","unstructured":"Garnett CE, Beasley N, Atul Bhattaram V et al (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13\u201318. https:\/\/doi.org\/10.1177\/0091270007307881","journal-title":"J Clin Pharmacol"},{"key":"9758_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/10543406.2018.1535498","volume":"29","author":"DP Huang","year":"2019","unstructured":"Huang DP, Chen J, Dang Q, Tsong Y (2019) Assay sensitivity in \u201cHybrid thorough QT\/QTc (TQT)\u201d study. J Biopharm Stat 29:378\u2013384. https:\/\/doi.org\/10.1080\/10543406.2018.1535498","journal-title":"J Biopharm Stat"},{"key":"9758_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8086","volume-title":"Using simulation studies to evaluate statistical methods","author":"TP Morris","year":"2019","unstructured":"Morris TP, White IR, Crowther MJ (2019) Using simulation studies to evaluate statistical methods. Stat, Med"},{"key":"9758_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/10543400801993002","volume":"18","author":"L Zhang","year":"2008","unstructured":"Zhang L, Dmitrienko A, Luta G (2008) Sample size calculations in thorough QT studies. J Biopharm Stat 18:468\u2013482. https:\/\/doi.org\/10.1080\/10543400801993002","journal-title":"J Biopharm Stat"},{"key":"9758_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/pst.463","volume":"10","author":"R Schall","year":"2011","unstructured":"Schall R, Ring A (2011) Mixed models for data from thorough QT studies: part 1. Assessment of marginal QT prolongation. Pharm Stat 10:265\u2013276. https:\/\/doi.org\/10.1002\/pst.463","journal-title":"Pharm Stat"},{"key":"9758_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/pst.1806","volume":"16","author":"DV Mehrotra","year":"2017","unstructured":"Mehrotra DV, Fan L, Liu F, Tsai K (2017) Enabling robust assessment of QTc prolongation in early phase clinical trials. Pharm Stat 16:218\u2013227. https:\/\/doi.org\/10.1002\/pst.1806","journal-title":"Pharm Stat"},{"key":"9758_CR14","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1016\/j.clinthera.2016.10.011","volume":"38","author":"HK Choi","year":"2016","unstructured":"Choi HK, Jung JA, Fujita T et al (2016) Population pharmacokinetic-pharmacodynamic analysis to compare the effect of moxifloxacin on QT interval prolongation between healthy Korean and Japanese subjects. Clin Ther 38:2610\u20132621. https:\/\/doi.org\/10.1016\/j.clinthera.2016.10.011","journal-title":"Clin Ther"},{"key":"9758_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pst.1638","volume":"13","author":"DV Mehrotra","year":"2014","unstructured":"Mehrotra DV (2014) A recommended analysis for 2 x 2 crossover trials with baseline measurements. Pharm Stat 13:376\u2013387. https:\/\/doi.org\/10.1002\/pst.1638","journal-title":"Pharm Stat"},{"key":"9758_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/10543400903582000","volume":"20","author":"SP Anand","year":"2010","unstructured":"Anand SP, Murray SC, Koch GG (2010) Sample size calculations for crossover thorough QT studies: satisfaction of regulatory threshold and assay sensitivity. J Biopharm Stat 20:587\u2013603. https:\/\/doi.org\/10.1080\/10543400903582000","journal-title":"J Biopharm Stat"},{"key":"9758_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/10543400903582000","volume":"20","author":"Z Meng","year":"2010","unstructured":"Meng Z, Kringle R, Chen X, Zhao PL (2010) Sample size calculation for thorough QT\/QTc study considering various factors related to multiple time points. J Biopharm Stat 20:563\u2013577. https:\/\/doi.org\/10.1080\/10543400903582000","journal-title":"J Biopharm Stat"},{"key":"9758_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/10543406.2013.735765","volume":"23","author":"W Li","year":"2013","unstructured":"Li W, Maes A, Quinlan M, Anand S (2013) Interdependence of baseline correction method and covariance structure for crossover TQT studies. J Biopharm Stat 23:82\u201397. https:\/\/doi.org\/10.1080\/10543406.2013.735765","journal-title":"J Biopharm Stat"},{"key":"9758_CR19","first-page":"329","volume-title":"Applied Mixed Models in Medicine","author":"H Brown","year":"2015","unstructured":"Brown H, Prescott R (2015) Trials with repeated measurements within visits. Applied Mixed Models in Medicine. Wiley, West Sussex, pp 329\u2013348"},{"key":"9758_CR20","volume-title":"SAS for mixed models: introduction and basic applications","author":"WW Stroup","year":"2018","unstructured":"Stroup WW, Milliken GA, Claassen EA, Wolfinger RD (2018) SAS for mixed models: introduction and basic applications. SAS Institute Inc., Cary"},{"key":"9758_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40264-013-0040-z","volume":"36","author":"J Zhang","year":"2013","unstructured":"Zhang J, Dang Q, Malik M (2013) Baseline correction in parallel thorough QT studies. Drug Saf 36:441\u2013453. https:\/\/doi.org\/10.1007\/s40264-013-0040-z","journal-title":"Drug Saf"},{"key":"9758_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/anec.12227","volume":"20","author":"G Ferber","year":"2015","unstructured":"Ferber G, Zhou M, Darpo B (2015) Detection of QTc effects in small studies-implications for replacing the thorough QT study. Ann Noninvasive Electrocardiol 20:368\u2013377. https:\/\/doi.org\/10.1111\/anec.12227","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"9758_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpt.361","volume":"100","author":"C Garnett","year":"2016","unstructured":"Garnett C, Needleman K, Liu J et al (2016) Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies. Clin Pharmacol Ther 100:170\u2013178. https:\/\/doi.org\/10.1002\/cpt.361","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-021-09758-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-021-09758-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-021-09758-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T13:24:43Z","timestamp":1630329883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-021-09758-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["9758"],"URL":"https:\/\/doi.org\/10.1007\/s10928-021-09758-9","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was approved by Institutional Review Board for Clinical Research, Tokai University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}